Deutsch English Français

Contact

EP2292246

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2292246

EP2292246 - Recombinant Newcastle Disease Virus [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 10.02.2012 Database last updated on 13.07.2024
Most recent event Tooltip	10.02.2012	Application deemed to be withdrawn	published on 14.03.2012 [2012/11]
Applicant(s)	For all designated states Bayer Pharma Aktiengesellschaft Müllerstrasse 178 13353 Berlin / DE
	[2011/34]
Former [2011/10]	For all designated states Bayer Schering Pharma Aktiengesellschaft Müllerstrasse 178 13353 Berlin / DE
Inventor(s)	01 / Beier, Rudolf Kiautschoustr. 1 13353 Berlin / DE
	02 / Bosslet, Klaus Im Amseltal 57 13465 Berlin / DE
	03 / Pühler, Florian Jules-Verne-Strasse 50 14089 Berlin / DE
	04 / Willuda, Jörg Staerkstr. 47a 16548 Glienicke/Nordbahn / DE
	[2011/10]
Application number, filing date	10175701.1	10.11.2005
	[2011/10]
Priority number, date	EP20040090432	12.11.2004 Original published format: EP 04090432
	[2011/10]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP2292246
	Date:	09.03.2011
	Language:	EN
	[2011/10]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	24.01.2011
Classification	IPC:	A61K35/76, C07K14/115	[2011/10]
	CPC:	C07K14/005 (EP,US); C12N7/00 (KR); A01K67/0271 (EP,US); A61K35/76 (KR); A61K35/768 (EP,US); A61K38/1709 (EP,US); (+) A61K38/2013 (EP,US); A61K38/47 (EP,US); A61K8/34 (EP,US); A61K8/35 (EP,US); A61K8/37 (EP,US); A61K8/4953 (EP,US); A61K8/922 (EP,US); A61K8/99 (EP,US); A61P35/00 (EP); A61Q19/08 (EP,US); A01K2267/0331 (EP,US); C07K2319/33 (EP,US); C12N2760/18122 (EP,US); C12N2760/18132 (EP,US); C12N2760/18143 (EP,US) (-)
	C-Set:	A61K38/1709, A61K2300/00 (US,EP); A61K38/2013, A61K2300/00 (EP,US); A61K38/47, A61K2300/00 (US,EP)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2011/10]
Extension states	AL	Not yet paid
	HR	Not yet paid
	MK	Not yet paid
	YU	Not yet paid
Title	German:	Rekombinantes Newcastle Disease Virus	[2011/10]
	English:	Recombinant Newcastle Disease Virus	[2011/10]
	French:	Virus recombiné de la Maladie de Newcastle	[2011/10]
Examination procedure	10.09.2011	Application deemed to be withdrawn, date of legal effect [2012/11]
	19.10.2011	Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2012/11]
Parent application(s) Tooltip	EP05818947.3 / EP1812026
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20050818947) is 14.03.2008
Fees paid	Renewal fee
	08.09.2010	Renewal fee patent year 03
	08.09.2010	Renewal fee patent year 04
	08.09.2010	Renewal fee patent year 05
	08.09.2010	Renewal fee patent year 06
	Penalty fee
	Additional fee for renewal fee
	30.11.2011	07 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[I] - LORENCE R M ET AL, "NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT: INDUCTION OF TUMOR NECROSIS FACTOR-ALPHA AND AUGMENTATION OF ITS CYTOTOXICITY", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, (19881019), vol. 80, no. 16, doi:10.1093/JNCI/80.16.1305, ISSN 0027-8874, pages 1305 - 1312, XP008037656 [I] 1-9 * abstract * * the whole document * DOI: http://dx.doi.org/10.1093/jnci/80.16.1305
		[I] - EBERT OLIVER ET AL, "Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer.", CANCER RESEARCH. 1 MAY 2004, (20040501), vol. 64, no. 9, ISSN 0008-5472, pages 3265 - 3270, XP002384970 [I] 1-9 * the whole document * DOI: http://dx.doi.org/10.1158/0008-5472.CAN-03-3753
		[A] - CSATARY L K ET AL, "BENEFICIAL TREATMENT OF PATIENTS WITH ADVANCED CANCER USING A NEWCASTLE DISEASE VIRUS VACCINE (MTH-68/H)", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, (19990101), vol. 19, ISSN 0250-7005, pages 635 - 638, XP008037650 [A] 1-9 * the whole document *
		[A] - LORENCE R M ET AL, "OVERVIEW OF PHASE I STUDIES OF INTRAVENOUS ADMINISTRATION OF PV701, AN ONCOLYTIC VIRUS", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON, GB, (20031201), vol. 5, no. 6, ISSN 1464-8431, pages 618 - 624, XP008064763 [A] 1-9 * the whole document *
		[A] - CASSEL W A ET AL, "NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT.", CANCER JUL 1965 LNKD- PUBMED:14308233, (196507), vol. 18, ISSN 0008-543X, pages 863 - 868, XP002615997 [A] 1-9 * the whole document *
		[A] - ENGEL-HERBERT INES ET AL, "Characterization of a recombinant Newcastle disease virus expressing the green fluorescent protein.", JOURNAL OF VIROLOGICAL METHODS, (200303), vol. 108, no. 1, ISSN 0166-0934, pages 19 - 28, XP002615996 [A] 1-9 * page 19 - page 27; figure 1; table 1 * DOI: http://dx.doi.org/10.1016/S0166-0934(02)00247-1
		[A] - NAKAYA T ET AL, "Recombinant Newcastle Disease Virus as a Vaccine Vector", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (20011201), vol. 75, no. 23, doi:10.1128/JVI.75.23.11868-11873.2001, ISSN 0022-538X, pages 11868 - 11873, XP002974292 [A] 1-9 * the whole document * DOI: http://dx.doi.org/10.1128/JVI.75.23.11868-11873.2001
		[A] - HUANG Z ET AL, "High-level expression of a foreign gene from the most 3'-proximal locus of a recombinant Newcastle disease virus.", THE JOURNAL OF GENERAL VIROLOGY JUL 2001 LNKD- PUBMED:11413385, (200107), vol. 82, no. Pt 7, ISSN 0022-1317, pages 1729 - 1736, XP002616279 [A] 1-9 * abstract *
		[A] - KRISHNAMURTHY S ET AL, "Recovery of a Virulent Strain of Newcastle Disease Virus from Cloned cDNA: Expression of a Foreign Gene Results in Growth Retardation and Attenuation", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, (20001205), vol. 278, no. 1, doi:10.1006/VIRO.2000.0618, ISSN 0042-6822, pages 168 - 182, XP004435793 [A] 1-9 * abstract * DOI: http://dx.doi.org/10.1006/viro.2000.0618
		[T] - PÜHLER F ET AL, "Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.", GENE THERAPY MAR 2008 LNKD- PUBMED:18200068, (200803), vol. 15, no. 5, ISSN 1476-5462, pages 371 - 383, XP002616517 DOI: http://dx.doi.org/10.1038/SJ.GT.3303095
	by applicant	EP0702085
		WO9966045
		WO0062735
		DE19932688
		WO0120989
		WO03005964
		US2003044384
		US6699479
		US2004072276
		US2004170607
		WO2005042505
		US2005175581
		- ADAMS, G.P.; WEINER, L.M., "Monoclonal antibody therapy of cancer", NAT BIOTECHNOL, (2005), vol. 23, pages 1147 - 1157
		- ALLEN, T.M., "Ligand-targeted therapeutics in anticancer therapy", NAT REV CANCER, (2002), vol. 2, pages 750 - 763
		- AMSTUTZ, P.; BINZ, H.K.; PARIZEK, P.; STUMPP, M.T.; KOHL, A.; GRUTTER, M.G.; FORRER, P.; PLUCKTHUN, A, "Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins", J BIOL CHEM, (2005), vol. 280, pages 24715 - 24722
		- ANTONIW, P.; SPRINGER, C.J.; BAGSHAWE, K.D.; SEARLE, F.; MELTON, R.G.; ROGERS, G.T.; BURKE, P.J.; SHERWOOD, R.F., "Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice", BR J CANCER, (1990), vol. 62, pages 909 - 914
		- BAGSHAWE, K.D.; SPRINGER, C.J.; SEARLE, F.; ANTONIW, P.; SHARMA, S.K.; MELTON, R.G.; SHERWOOD, R.F., "A cytotoxic agent can be generated selectively at cancer sites", BR J CANCER, (1988), vol. 58, pages 700 - 703
		- BATRA, J.K.; FITZGERALD, D.J.; CHAUDHARY, V.K.; PASTAN, "Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv)", MOL CELL BIOL, (1991), vol. 11, pages 2200 - 2205
		- BATRA, J.K.; KASPRZYK, P.G.; BIRD, R.E.; PASTAN; KING, C.R., "Recombinant anti- erbB2 immunotoxins containing Pseudomonas exotoxin", PROC NATL ACAD SCI USA, (1992), vol. 89, pages 5867 - 5871
		- BELL, J.C.; GARSON, K.A.; LICHTY, B.D.; STOJDL, D.F., "Oncolytic viruses: programmable tumor hunters", CURR GENE THER, (2002), vol. 2, pages 243 - 254
		- BINZ, H.K.; AMSTUTZ, P.; KOHL, A.; STUMPP, M.T.; BRIAND, C.; FORRER, P.; GRUTTER, M.G.; PLUCKTHUN, A., "High-affinity binders selected from designed ankyrin repeat protein libraries", NAT BIOTECHNOL, (2004), vol. 22, pages 575 - 582
		- BOSSLET, K.; CZECH, J.; LORENZ, P.; SEDLACEK, H.H.; SCHUERMANN, M.; SEEMANN, G., "Molecular and functional characterisation of a fusion protein suited for tumor specific prodrug activation", BR J CANCER, (1992), vol. 65, pages 234 - 238
		- CARNEMOLLA, B.; BORSI, L.; BALZA, E.; CASTELLANI, P.; MEAZZA, R.; BERNDT, A.; FERRINI, S.; KOSMEHL, H.; NERI, D.; ZARDI, L., "Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix", BLOOD, (2002), vol. 99, pages 1659 - 1665
		- CHAUDHARY, V.K.; GALLO, M.G.; FITZGERALD, D.J.; PASTAN, "A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin", PROC NATL ACAD SCI USA, (1990), vol. 87, pages 9491 - 9494
		- CHAUDHARY, V.K.; QUEEN, C.; JUNGHANS, RP.; WALDMANN, T.A.; FITZGERALD, D.J; PASTAN, "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin", NATURE, (1989), vol. 339, pages 394 - 397
		- CHIOCCA, E.A., "Oncolytic viruses", NAT REV CANCER, (2002), vol. 2, pages 938 - 950
		- CSATARY, L.K.; GOSZTONYI, G.; SZEBERENYI, J.; FABIAN, Z.; LISZKA, V.; BODEY, B.; CSATARY, C.M., "MTH-68/H oncolytic viral treatment in human high-grade gliomas", J NEUROONCOL, (2004), vol. 67, pages 83 - 93
		- DE LORENZO, C.; ARCIELLO, A.; COZZOLINO, R.; PALMER, D.B.; LACCETTI, P.; PICCOLI, R.; D'ALESSIO, G., "A fully human antitumor immunoRNase selective for ErbB-2- positive carcinomas", CANCER RES, (2004), vol. 64, pages 4870 - 4874
		- ENGEL-HERBERT, I.; WERNER, O.; TEIFKE, J.P.; MEBATSION, T.; METTENLEITER, T.C.; ROMER-OBERDORFER, A., "Characterization of a recombinant Newcastle disease virus expressing the green fluorescent protein", J VIROL METHODS, (2003), vol. 108, pages 19 - 28
		- FERRARA, N.; HILLAN, K.J.; GERBER, H.P; NOVOTNY, W., "Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer", NAT REV DRUG DISCOV, (2004), vol. 3, pages 391 - 400
		- FORD, K.G.; SOUBERBIELLE, B.E.; DARLING, D; FARZANEH, F., "Protein transduction: an alternative to genetic intervention?", GENE THER, (2001), vol. 8, pages 1 - 4
		- GEORGAKIS, G.V.; LI, Y.; HUMPHREYS, R.; ANDREEFF, M.; O'BRIEN, S.; YOUNES, M.; CARBONE, A.; ALBERT, V.; YOUNES, A., "Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin-and bortezomib-induced cell death", BR J HAEMATOL, (2005), vol. 130, pages 501 - 510
		- GERBER, H.P.; FERRARA, N., "Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies", CANCER RES, (2005), vol. 65, pages 671 - 680
		- HANAHAN, D.; WEINBERG, R.A., "The hallmarks of cancer", CELL, (2000), vol. 100, pages 57 - 70
		- HERBST, R.S.; LANGER, C.J, "Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers", SEMIN ONCOL, (2002), vol. 29, pages 27 - 36
		- HOGBOM, M.; EKLUND, M.; NYGREN, P.A; NORDLUND, P., "Structural basis for recognition by an in vitro evolved affibody", PROC NATL ACAD SCI USA, (2003), vol. 100, pages 3191 - 3196
		- HUANG, Z.; ELANKUMARAN, S.; YUNUS, A.S.; SAMAL, S.K., "A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV", J VIROL, (2004), vol. 78, pages 10054 - 10063
		- HUANG, Z.; KRISHNAMURTHY, S.; PANDA, A.; SAMAL, S.K., "High-level expression of a foreign gene from the most 3'-proximal locus of a recombinant Newcastle disease virus", J GEN VIROL, (2001), vol. 82, pages 1729 - 1736
		- KREITMAN, R.J.; CHAUDHARY, V.K.; WALDMANN, T.A.; HANCHARD, B.; CRANSTON, B.; FITZGERALD, D.J.; PASTAN, "Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia", LEUKEMIA, (1993), vol. 7, pages 553 - 562
		- KREITMAN, R.J.; PASTAN, "Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor", BIOCHEM J, (1995), vol. 307, pages 29 - 37
		- KRISHNAMURTHY, S.; HUANG, Z.; SAMAL, S.K., "Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation", VIROLOGY, (2000), vol. 278, pages 168 - 182
		- KUAN, S.F.; BYRD, J.C.; BASBAUM, C.B.; KIM, Y.S, "Characterization of quantitative mucin variants from a human colon cancer cell line", CANCER RES, (1987), vol. 47, pages 5715 - 5724
		- LADNER, R.C.; LEY, A.C.; 2001, "Novel frameworks as a source of high-affinity ligands", CURR OPIN BIOTECHNOL, vol. 12, pages 406 - 410
		- "Paramyxoviridae: The Viruses And Their Replication", LAMB, R.A.; KOLAKOFSKY, D., Virology, LIPPINCOTT WILLIAMS & WILKINS, (2001), pages 1305 - 1485
		- LORENCE, R.M.; PECORA, A.L.; MAJOR, P.P.; HOTTE, S.J.; LAURIE, S.A.; ROBERTS, M.S.; GROENE, W.S.; BAMAT, M.K., "Overview of phase I studies of intravenous administration of PV701, an oncolytic virus", CURR OPIN MOL THER, (2003), vol. 5, pages 618 - 624
		- MIZUKAMI, Y.; JO, W.S.; DUERR, E.M.; GALA, M.; LI, J.; ZHANG, X.; ZIMMER, M.A.; ILIOPOULOS, O.; ZUKERBERG, L.R.; KOHGO, Y., "Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells", NAT MED, (2005), vol. 11, pages 992 - 997
		- NAKAYA, T.; CROS, J.; PARK, M.S.; NAKAYA, Y.; ZHENG, H.; SAGRERA, A.; VILLAR, E.; GARCIA-SASTRE, A.; PALESE, P., "Recombinant Newcastle disease virus as a vaccine vector", J VIROL, (2001), vol. 75, pages 11868 - 11873
		- NOONBERG, S.B.; BENZ, C.C., "Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents", DRUGS, (2000), vol. 59, pages 753 - 767
		- NORD, K.; GUNNERIUSSON, E., "Ligands selected from combinatorial libraries of protein A for use in affinity capture of apolipoprotein A-1 M and taq DNA polymerase", J BIOTECHNOL, (2000), vol. 80, pages 45 - 54
		- ROFFLER, S.R.; WANG, S.M.; CHERN, J.W.; YEH, M.Y.; TUNG, E., "Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate", BIOCHEM PHARMACOL, (1991), vol. 42, pages 2062 - 2065
		- ROMER-OBERDORFER, A.; MUNDT, E.; MEBATSION, T.; BUCHHOLZ, U.J.; METTENLEITER, T.C., "Generation of recombinant lentogenic Newcastle disease virus from cDNA", J GEN VIROL, (1999), vol. 80, pages 2987 - 2995
		- "Antibody guided enzyme nitrile therapy (Agent): in vitro cytotoxicity and in vivo tumor localisation", ROWLINSON-BUSZA, G.; BAMIAS, A.; KRAUSZ, T.; EPENETOS, A.A., Monoclonal Antibodies 2. Applications in Clinical Oncology., CHAPMAN AND HALL, (1992), pages 111 - 118
		- RUSSELL, S.J., "RNA viruses as virotherapy agents", CANCER GENE THER, (2002), vol. 9, pages 961 - 966
		- SALGALLER, M.L., "Technology evaluation: bevacizumab, Genentech/Roche", CURR OPIN MOL THER, (2003), vol. 5, pages 657 - 667
		- SCHNELL, M.J.; MEBATSION, T.; CONZELMANN, K.K., "Infectious rabies viruses from cloned cDNA", EMBO J, (1994), vol. 13, pages 4195 - 4203
		- SINKOVICS, J.G.; HORVATH, J.C., "Newcastle disease virus (NDV): brief history of its oncolytic strains", J CLIN VIROL, (2000), vol. 16, pages 1 - 15
		- SKERRA, A., "Lipocalins as a scaffold", BIOCHIM BIOPHYS ACTA, (2000), vol. 1482, pages 337 - 350
		- STOJDL, D.F.; LICHTY, B.D.; TENOEVER, B.R.; PATERSON, J.M.; POWER, A.T.; KNOWLES, S.; MARIUS, R.; REYNARD, J.; POLIQUIN, L.; ATKIN, "VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents", CANCER CELL, (2003), vol. 4, pages 263 - 275
		- VOGELSTEIN, B.; KINZLER, K.W, "Cancer genes and the pathways they control", NAT MED, (2004), vol. 10, pages 789 - 799
		- WALTENBERGER, J.; CLAESSON-WELSH, L.; SIEGBAHN, A.; SHIBUYA, M.; HELDIN, C.H., "Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor", J BIOL CHEM, (1994), vol. 269, pages 26988 - 26995
		- WANG, S.M.; CHERN, J.W.; YEH, M.Y.; NG, J.C.; TUNG, E.; ROFFLER, S.R, "Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy", CANCER RES, (1992), vol. 52, pages 4484 - 4491
		- WARREN, R.S.; YUAN, H.; MATLI, M.R.; GILLETT, N.A.; FERRARA, N., "Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis", J CLIN INVEST, (1995), vol. 95, pages 1789 - 1797
		- ZEWE, M.; RYBAK, S.M.; DUBEL, S.; COY, J.F.; WELSCHOF, M.; NEWTON, D.L.; LITTLE, M., "Cloning and cytotoxicity of a human pancreatic RNase immunofusion", IMMUNOTECHNOLOGY, (1997), vol. 3, pages 127 - 136
		- ZHAO, H.; PEETERS, B.P., "Recombinant Newcastle disease virus as a viral vector: effect of genomic location of foreign gene on gene expression and virus replication", J GEN VIROL, (2003), vol. 84, pages 781 - 788

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p